Legal & General Group
PDLI

Legal & General Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Legal & General Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-23,284
Closed -$73K – 3533
2020
Q3 		$73K Sell
23,284
-4,588
-16% -$14.7K ﹤0.01% 2577
2020
Q2 		$81K Hold
27,872
– – ﹤0.01% 2590
2020
Q1 		$79K Sell
27,872
-6,098
-18% -$19.7K ﹤0.01% 2478
2019
Q4 		$111K Hold
33,970
– – ﹤0.01% 2566
2019
Q3 		$73K Buy
33,970
+8,834
+35% +$23.6K ﹤0.01% 2619
2019
Q2 		$79K Sell
25,136
-3,100
-11% -$10.1K ﹤0.01% 2612
2019
Q1 		$105K Buy
28,236
+1,558
+6% +$5.26K ﹤0.01% 2471
2018
Q4 		$77K Buy
26,678
+5,197
+24% +$14.3K ﹤0.01% 2538
2018
Q3 		$56K Hold
21,481
– – ﹤0.01% 2722
2018
Q2 		$50K Sell
21,481
-6,178
-22% -$17.2K ﹤0.01% 2752
2018
Q1 		$81K Sell
27,659
-10,426
-27% -$28.5K ﹤0.01% 2543
2017
Q4 		$106K Sell
38,085
-6,402
-14% -$19.7K ﹤0.01% 2554
2017
Q3 		$151K Buy
44,487
+4,336
+11% +$12.1K ﹤0.01% 2441
2017
Q2 		$101K Sell
40,151
-13,549
-25% -$31.2K ﹤0.01% 2603
2017
Q1 		$120K Sell
53,700
-239,656
-82% -$530K ﹤0.01% 2453
2016
Q4 		$622K Buy
293,356
+13,142
+5% +$36.7K ﹤0.01% 1920
2016
Q3 		$935K Buy
280,214
+78,477
+39% +$249K ﹤0.01% 1427
2016
Q2 		$632K Buy
201,737
+48,570
+32% +$162K ﹤0.01% 1277
2016
Q1 		$509K Sell
153,167
-14,337
-9% -$44.7K ﹤0.01% 1304
2015
Q4 		$593K Buy
167,504
+58,338
+53% +$244K ﹤0.01% 1285
2015
Q3 		$549K Hold
109,166
– – ﹤0.01% 1269
2015
Q2 		$702K Buy
109,166
+5,809
+6% +$38.9K ﹤0.01% 1227
2015
Q1 		$729K Buy
103,357
+22,512
+28% +$163K ﹤0.01% 1200
2014
Q4 		$624K Buy
80,845
+342
+0.4% +$2.71K ﹤0.01% 1199
2014
Q3 		$603K Buy
80,503
+24,717
+44% +$229K ﹤0.01% 1165
2014
Q2 		$540K Hold
55,786
– – ﹤0.01% 1157
2014
Q1 		$464K Hold
55,786
– – ﹤0.01% 1145
2013
Q4 		$471K Hold
55,786
– – ﹤0.01% 1153
2013
Q3 		$445K Buy
55,786
+30,405
+120% +$244K ﹤0.01% 1141
2013
Q2 		$196K Buy
+25,381
New +$198K ﹤0.01% 1208

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Legal & General Group's PDLI Position: Q4 2020 in Review

Legal & General Group sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 23,284 shares — an estimated $73K sold.

Legal & General Group first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $935K in Q3 2016. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Legal & General Group reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Legal & General Group sold 23,284 PDL BioPharma, Inc. shares in Q4 2020, an estimated $73K.
  • Legal & General Group first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
  • Legal & General Group's PDL BioPharma, Inc. position peaked at $935K in Q3 2016.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Legal & General Group's 13F filing for Q4 2020, filed 12 Feb 2021.